Search Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupEndocrine and Neuroendocrine OncologyThoracic TumorsTumor, regardless of entityDiseaseLung Carcinoma, Non-Small CellThyroid CancerTumor Biomarker DefinedSubgroupRET fusion positiveICD10C34.-C73MeSHNeoplasmsThyroid NeoplasmsSequenceChemotherapyChemo-substanceSelpercatinibChemo-substanceSelpercatinibChemo-substanceSelpercatinibChemo-substanceSelpercatinibNo. Substances1 RadiotherapySupportive therapySupportive substanceSupportive substanceSupportive substanceSupportive substanceNo. SubstancesProtocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationseveral possibleTherapy phaseTherapy intentionpalliativeRisksConstipationDiarrheaEmetogenicityHepatotoxicityHypertensionPyrexiaQTc Time ExtensionRashThrombocytopenia below 50 000/µl only studiesPublicationAuthorDrilon ADiseaseRET-bedingte Tumoren, Zweitlinie oder höher, ECOG 0-2OriginMemorial Sloan Kettering Cancer Center and Weill Cornell Medical College, LIBRETTO-001Protocols in Revision 1 protocol foundProtocols under revision.Selpercatinib 160, Tumor Biomarker Defined (PID1732 V1.0)
